Pacific Biosciences is trading 5.05% up at $1.17, moving alongside stronger broader markets on August 13, 2026, as softer-than-expected producer prices reinforced expectations for steady Federal Reserve policy.
- The S&P 500 and Nasdaq Composite are both up more than 0.5%.
- No clear company-specific announcement explaining the move was identified.
- Recent earnings concerns remain relevant, including lowered 2026 revenue guidance and delayed cash-flow breakeven expectations.